Drug Trial Radar · NCT06413680
A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
Last checked: Nov 19, 2026Latest source record: Apr 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
240
Planned (sponsor's estimate)
Start
Sep 23, 2024
Primary completion
Feb 3, 2030
Study completion Feb 3, 2030
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- May 14, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is researching an experimental drug called REGN10597 alone or in combination with another drug called cemiplimab (called "study drug(s)"). The study is focused on patients with certain solid tumors that are in an advanced stage. The aim of the study is to see how safe, tolerable, and effective the study drug(s) are. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug(s) * How much study drug(s) is in the blood at different times * Whether the body makes antibodies against the study drug(s) (which could make the study drug(s) less effective or could lead to side effects)
Conditions
- Melanoma
- Clear-Cell Renal-Cell Carcinoma (ccRCC)
- Advanced Solid Tumors
Interventions
REGN10597Drug
Administered per the protocol
CemiplimabDrug
Administered per the protocol
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Dose-Limiting Toxicities (DLTs)Time frame: Up to Day 29
- Incidence of Treatment-Emergent Adverse Event (TEAEs)Time frame: Approximately 6 Years
- Incidence of Serious Adverse Events (SAEs)Time frame: Approximately 6 Years
- Incidence of TEAEs leading to treatment discontinuationTime frame: Approximately 6 Years
- Incidence of TEAEs leading to deathTime frame: Approximately 6 Years
- Number of participants with Grade 3 laboratory abnormalitiesTime frame: Approximately 6 Years
- Objective Response Rate (ORR) per Response Evaluation Criteria In Solid Tumors (RECIST 1.1) criteria by investigator assessmentTime frame: Approximately 6 Years
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
USC Norris Comprehensive Cancer Center
Los Angeles, California · Recruiting
University of California San Francisco (UCSF)
San Francisco, California · Recruiting
Yale School of Medicine
North Haven, Connecticut · Recruiting
University of Chicago
Chicago, Illinois · Recruiting
Start Midwest Cancer Research
Grand Rapids, Michigan · Recruiting
Northwell Health
Lake Success, New York · Recruiting
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina · Recruiting
University of Pittsburgh Medical Center - Hillman Cancer Center
Pittsburgh, Pennsylvania · Recruiting
MD Anderson Cancer Center
Houston, Texas · Recruiting
Next Oncology
San Antonio, Texas · Recruiting
The Start Center for Cancer Care
San Antonio, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.